TGFBR2 and adenocarcinoma: The mutation rates of Tgfbr2 in the progressed SCCs appeared to increase as compared those detected in the DMBA-treated organoid-derived adenocarcinomas observed in the present study, suggesting an association between squamous cell differentiation and the function of TGFBR2.